Mining fungi: a fountain of new medicines?
While fungi are a rich source of natural molecules, it has historically been hard to identify and capture these in a systematic way. Now a new technology platform, developed by researchers at Northwestern University and their partners, promises to speed up the process dramatically. Could this lead to a gold rush of drug discoveries? Abi Miller finds out.
Osteoporosis breakthrough: positive news in a field plagued by bad press
A new study has shown that the use of a common osteoporosis drug with anti-inflammatory medication is linked to a lower risk of hip fracture. This is just one of a range of exciting developments in the field, which also include the approval of a new drug in the US and an increased focus in the UK on screening and risk assessment tools. Elly Earls reports.
One in five: why the UK pharmaceutical industry is going to court over spending caps
The ABPI is taking UK drug regulator NICE to court over new spending caps, which will affect one in five of all new approved drugs. Abi Millar looks into the issues surrounding this important legal contest.
August's top stories: Mylan launched anti-retroviral treatments, Fosun updated on $1.3bn takeover
Mylan launched three generic anti-retroviral treatments for HIV patients in Canada, and Fosun updated on $1.3bn takeover of Indian drugmaker Gland Pharma. Pharmaceutical-technology.com wraps up the key headlines from August.
Is Amazon gearing up to take on the US pharmacy market?
Reports that Amazon is considering breaking into the US pharmacy industry have sent ripples up and down the drug supply chain. Is there enough evidence to suggest that the retail and tech giant is truly serious about making such a move, and what could the implications be for the major players in the complex US drugs distribution and retail market?